NVS — NOVARTIS AG catalysts

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

12 verified catalyst event(s) for NOVARTIS AG (ticker NVS). Each is linked to its official source. Verified as of 2026-09-20.

Next verified catalyst

2026-09-24 — An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, · official source ↗

Upcoming

Date	Event	Company	Drug	Official source & verification
2026-09-24 in 4d ESTIMATED	READOUT An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 Phase 1/2 · Systemic Lupus Erythematosus, Lupus Nephritis	NVS NOVARTIS AG	YTB323	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Phase 1/2 · KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung	NVS NOVARTIS AG	JDQ443, trametinib, Ribociclib, cetuxima	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-01 in 11d ESTIMATED	READOUT A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular De Phase 2 · Age-Related Macular Degeneration	NVS NOVARTIS AG	Iptacopan (LNP023)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-15 in 25d ESTIMATED	READOUT An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combin Phase 2 · Metastatic Castration Resistant Prostate Cancer (mCRPC)	NVS NOVARTIS AG	AAA617, ARPI: Abiraterone, ARPI: Enzalut	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-26 in 1mo ESTIMATED	READOUT Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Additio Phase 3 · Coronary Artery Disease	NVS NOVARTIS AG	Inclisiran sodium 300 mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-29 in 1mo ESTIMATED	READOUT Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in P Phase 3 · Primary Immune Thrombocytopenia (ITP)	NVS NOVARTIS AG	Ianalumab, Corticosteroids	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-03 in 1mo ESTIMATED	READOUT 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, Phase 3 · Chronic Spontaneous Urticaria	NVS NOVARTIS AG	LOU064 (blinded)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-05 in 2mo ESTIMATED	READOUT Pediatric Long-Term Follow-up and Rollover Study Phase 4 · Diffuse Astrocytoma, Anaplastic Astrocytoma	NVS NOVARTIS AG	dabrafenib, trametinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-14 in 3mo ESTIMATED	READOUT Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moder Phase 2 · Metastatic Castration-Resistant Prostate Cancer (mCRPC)	NVS NOVARTIS AG	AAA617, 68Ga-PSMA-11	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-23 in 3mo ESTIMATED	READOUT A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients Phase 2 · Prostatic Neoplasm	NVS NOVARTIS AG	AAA617, AAA517, Piflufolastat F 18, ARPI	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-30 in 3mo ESTIMATED	READOUT Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients Phase 3 · Tuberous Sclerosis Complex	NVS NOVARTIS AG	everolimus	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-30 in 3mo ESTIMATED	READOUT Iptacopan in Patients With ANCA Associated Vasculitis Phase 2 · Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis	NVS NOVARTIS AG	Iptacopan, Rituximab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change